Key Developments For Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc. (CYTX.O) (Consolidated Issue listed on NASDAQ Global Market)
Cytori Therapeutics, Inc. Reports Preclinical Results that Suggest Adipose-Derived Regenerative Cells may Reverse Periodontal Disease
Cytori Therapeutics, Inc. reported results from their preclinical study on the use of uncultured adipose-derived regenerative cells (ADRCs) in the treatment of critical periodontal defects in a rat model. The results suggest that the use of ADRCs may reverse the effects of periodontal disease, evidenced by significantly improved alveolar bone healing and decreased gingival (gum) invasion of the defect. As part of the study design, 20 immuno-deficient rats were treated for four critical defects in each. One of the defects was treated with uncultured human ADRCs and a second with cultured human adipose-derived stem cells (ADSC`s), both in Platelet Rich Plasma (PRP). A third was treated with PRP alone and a fourth with no treatment. The study`s results showed that at six weeks post-treatment the defects treated with the uncultured ADRCs and with the cultured ADSCs showed a statistically significant (p<0.001) improvement in healing of the alveolar bone compared to the two controls. Furthermore, uncultured ADRC and cultured ADSC treatment significantly decreased the gingival invasion of the defect when compared to no treatment (p<0.001) and PRP alone (p<0.05).
Cytori Therapeutics, Inc. Reaffirms FY 2009 Product Revenue Guidance
Cytori Therapeutics, Inc. maintained its guidance of $10 million in product revenue for fiscal 2009.
Cytori Therapeutics, Inc. Comments on Patent Appeal
Cytori Therapeutics, Inc. announced that it has been informed that the United States Federal Court in the Central District of California upheld a June 2008 decision relating to U.S. patent number 6,777,231 (the 231 patent). The Court's decision has no impact on Cytori's products or clinical applications under development. Cytori's products do not practice the '231 patent. Cytori's Celution System yields an output comprising a diverse mixture of cells found in adipose tissue whereas the '231 patent covers a narrowly defined population of adipose derived adult stem cells in an environment substantially free of other cellular materials found in adipose tissue. The narrowly defined population of cells that are covered by the '231 patent require different isolation or processing techniques, which the Celution System, by design, does not perform.
Cytori Therapeutics Inc. Expands Patent Protection For Celution System and Uses For Adipose Derived Stem And Regenerative Cells
Cytori Therapeutics Inc. announced that it has recently received a Notice of Allowance from the U.S. Patent and Trademark Office related to uses of the Celution System for the treatment of bone related disorders. Specifically, the allowed claims cover prosthetic devices that can be seeded with adipose derived stem and regenerative cells for use in bone healing and regeneration. In addition, the Company received a second Notice of Allowance related to methods of obtaining clinically safe outputs from the Celution System. The allowed claims cover methods of testing the Celution output for contaminants such as red blood cells, lipids, enzymes, aggregates, and endotoxins, among other things.
Cytori Therapeutics Inc. Receives Equity Commitment; Investment Fund To Purchase Up To 7.15 Million Shares Over Next 12 Months
Cytori Therapeutics Inc. announced that it has entered into an equity agreement with Seaside 88, LP (Seaside). Under the terms of the agreement, Seaside has committed to purchase up to 7.15 million Cytori common shares, in a series of closings every two weeks in the amount of 275,000 shares each for a total of up to 26 purchases. Cytori and Seaside expect to close the first sale of 275,000 shares for gross proceeds of $852,000 on June 22, 2009. Cytori has the right to discontinue the agreement between the 13th and 14th closings, based on Cytori's assessment of its financing needs at that time. The purchase price for all closings executed under the agreement is determined by applying a 13% discount to a volume-weighted-average price (VWAP) of Cytori`s common stock. The price of the shares to be sold at today`s initial closing will be based on Cytori`s share price on June 19. The pricing of all subsequent closings will be based on Cytori`s share price for the ten trading days preceding each closing date. The scheduled closings will not take place if the Cytori`s VWAP for the 10 preceding trading days is less than $2.50.
